Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Liver Dis. 2008 Nov;12(4):733-46, vii. doi: 10.1016/j.cld.2008.07.007.

The global impact of hepatic fibrosis and end-stage liver disease.

Author information

  • 1Division of Gastroenterology and Hepatology (PL 6), Mayo Clinic College of Medicine, Rochester, MN 55905, USA.

Abstract

Hepatic fibrosis is an integral part in the progression of chronic liver disease, ultimately leading to cirrhosis and hepatocellular carcinoma. Globally, alcohol consumption, hepatitis B (HBV) and hepatitis C (HCV) have been the main causes of cirrhosis. More recently, the increasing prevalence of obesity and the metabolic syndrome has resulted in increasing incidence of cirrhosis secondary to nonalcoholic fatty liver disease (NAFLD), especially in developed countries. Chronic liver disease and cirrhosis are important causes of morbidity and mortality in the world. Moreover, the burden of chronic liver disease is projected to increase, due in part to the increasing prevalence of end-stage liver disease and HCC secondary to NAFLD and HCV.

PMID:
18984463
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk